1. Home
  2. ZLAB vs FIHL Comparison

ZLAB vs FIHL Comparison

Compare ZLAB & FIHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • FIHL
  • Stock Information
  • Founded
  • ZLAB 2013
  • FIHL 2014
  • Country
  • ZLAB China
  • FIHL Bermuda
  • Employees
  • ZLAB N/A
  • FIHL N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • FIHL
  • Sector
  • ZLAB Health Care
  • FIHL
  • Exchange
  • ZLAB Nasdaq
  • FIHL Nasdaq
  • Market Cap
  • ZLAB 3.6B
  • FIHL 1.8B
  • IPO Year
  • ZLAB 2017
  • FIHL 2023
  • Fundamental
  • Price
  • ZLAB $36.40
  • FIHL $16.19
  • Analyst Decision
  • ZLAB Buy
  • FIHL Hold
  • Analyst Count
  • ZLAB 5
  • FIHL 7
  • Target Price
  • ZLAB $54.28
  • FIHL $20.29
  • AVG Volume (30 Days)
  • ZLAB 886.6K
  • FIHL 810.6K
  • Earning Date
  • ZLAB 08-05-2025
  • FIHL 08-13-2025
  • Dividend Yield
  • ZLAB N/A
  • FIHL 2.47%
  • EPS Growth
  • ZLAB N/A
  • FIHL N/A
  • EPS
  • ZLAB N/A
  • FIHL N/A
  • Revenue
  • ZLAB $418,326,000.00
  • FIHL $2,558,400,000.00
  • Revenue This Year
  • ZLAB $44.07
  • FIHL $24.21
  • Revenue Next Year
  • ZLAB $49.13
  • FIHL $5.09
  • P/E Ratio
  • ZLAB N/A
  • FIHL N/A
  • Revenue Growth
  • ZLAB 43.72
  • FIHL 23.93
  • 52 Week Low
  • ZLAB $16.01
  • FIHL $14.17
  • 52 Week High
  • ZLAB $44.34
  • FIHL $21.32
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 52.67
  • FIHL 45.88
  • Support Level
  • ZLAB $34.79
  • FIHL $16.15
  • Resistance Level
  • ZLAB $36.73
  • FIHL $16.98
  • Average True Range (ATR)
  • ZLAB 1.23
  • FIHL 0.45
  • MACD
  • ZLAB -0.46
  • FIHL 0.02
  • Stochastic Oscillator
  • ZLAB 25.91
  • FIHL 46.76

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.

Share on Social Networks: